目的　明确胶质瘤及患者脑脊液 (CSF)中端粒酶的活性表达情况。方法　采用TRAP(telomericrepeatamplificationprotocol)法检测 5 0例胶质瘤、 3例转移瘤及 17例肿瘤端粒酶呈阳性患者CSF中端粒酶活性表达情况。统计学处理采用 χ2 检验。结果　 (1)肿瘤端粒酶 :胶质瘤 (WHO分级 )中阳性率为 2 2 /5 0 (4 4 0 % ) ,其中Ⅰ级为 3/16 (18 8% ) ,Ⅱ级为 3/12 (2 5 0 % )。Ⅲ级为 9/14(6 4 3% ) ,Ⅳ级为 7/8(87 5 % ) ,3例转移性瘤端粒酶活性检测为 3/3(10 0 % )。胶质瘤分级越高 ,端粒酶活性检出率就越高 (P <0 0 0 5 ) ,2 5例Ⅲ级以上恶性脑肿瘤中 (包括转移性低分化癌 ) 19例端粒酶活性表达阳性 (76 0 % ) ,明显高于Ⅱ级以下胶质瘤 (6 /2 8,2 1 4% ) (P <0 0 0 5 )。 (2 )CSF中端粒酶的活性 :6例术前、 17例术后采取脑脊液 (包括 5例术前曾采取CSF的患者 ;其切除的肿瘤中端粒酶检测均为阳性 )端粒酶检出率分别为 3/6 (5 0 0 % )和 12 /17(70 6 % )。 3例术前CSF呈阴性的患者 ,检测 2例术后CSF呈阳性。结论　 (1)端粒酶可能是新的恶性脑肿瘤的瘤标 ;(2 )检测脑脊液中端粒酶的活性应作为脑胶质瘤诊断的辅助检查 ,以便早期发现恶性胶质瘤或判断肿瘤的恶性程度 ;(3)对首次基本全切、短期内复发的胶质瘤或 Objective To determine the expression of telomerase activity in glioma and cerebrospinal fluid (CSF) of patients. Methods Telomerase activity (TRAP) was used to detect telomerase activity in CSF of 50 patients with glioma, 3 metastases and 17 patients with telomerase positive telomerase activity. Statistical analysis using χ2 test. Results (1) The positive rate of tumor telomerase: glioma (WHO grade) was 2 2/50 (4 40%), of which Grade I was 3/16 (18.8%) and Grade II was 3 / 12 (25%). Grade Ⅲ was 9/14 (64.3%), grade Ⅳ was 7/8 (87.5%), and telomerase activity was detected in 3 of 3 (10%) in 3 cases. The higher the grade of glioma, the higher the detection rate of telomerase activity (P <0.05), the telomerase activity of 19 cases in 25 malignant brain tumors of grade Ⅲ or above (including metastatic poorly differentiated carcinoma) (76.0%) was significantly higher than that of grade Ⅱ glioma (6/28, 14%) (P <0.05). (2) Activity of telomerase in CSF: Six patients were preoperatively and 17 patients were treated with cerebrospinal fluid (including 5 patients who had received CSF before surgery; telomerase activity was positive in excised tumors); telomerase The detection rates were 3/6 (500%) and 12/17 (70.6%), respectively. Three patients with negative CSF before surgery were positive in 2 cases after operation. Conclusions (1) Telomerase may be the tumor marker of new malignant brain tumors; (2) The detection of telomerase activity in cerebrospinal fluid should be used as an auxiliary examination for the diagnosis of gliomas so that early detection of malignant gliomas or tumor Of the degree of malignancy; (3) for the first time a total complete resection, short-term recurrence of glioma or